NCT05673252Active, not recruiting
CERvical Cancer The InFlammatory Index (CERTIFIKO)
CERvical Cance The InFlammatory Index as a Predictor of risK Stratification:an Observational Study
Source: ClinicalTrials.gov · Last updated 7 Aug 2026
Brief summary (registry, in English)
Although significant advances in screening and treatment , cervical cancer is the fifth most common female cancer in Europe. Major prognostic factors for oncological outcome are used to categorise patients at high, intermediate and low risk groups and to define the type of radical hysterectomy according "Querleu-Morrow classification". The goal of this prospective observational study is to evaluate the association between several inflammatory markers and risk groups according European guidelines in women with cervical cancer Human Papillomavirus (HPV)-associated, in order to optimize the treatment.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 128 (estimated)
- First submitted
- 2 Dec 2022
- Start date
- 18 Jul 2023
- Primary completion date
- 18 Dec 2025
- Lead sponsor
- University of Campania Luigi Vanvitelli
- Diseases
- Cervical cancer
- NCT number
- NCT05673252
What you commit to
- Study type: Observational
- Planned participants: 128
- From 18 Jul 2023 to the primary completion date, 18 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Synchronous tumors or cancer diagnosis in the previous 3 years
- Patients undergoing steroid therapy in the last 30 days prior to recruitment
Other illness
- Patients with chronic inflammatory diseases (IBDs; rheumatic conditions)
Other
- Patients unfit to plead
Who the study is looking for
- At least 18-year-old patients.
- Patients histologically diagnosed with cervical cancer (squamous cell carcinoma or adenocarcinoma HPV- associated)
- Patients with (2018 FIGO) stage ≤ IB2 ("Early Cervical Cancer")
- Patients undergoing full-body CT-scan 30 days before enrollment.
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Universita degli Studi della Campania Luigi Vanvitelli Coordinator of this site? Confirm its status | Naples | Italy | Unknown status |
Related publications
- Exploratory Analysis of Systemic Inflammatory Indices Across Locoregional Tumor Progression Parameters in Cervical Cancer: The CERTIFIKO Prospective Study.Medicina (Kaunas) · 2026 · PMID 42654467
This page is information, not medical advice. Discuss any trial with your doctor.